Resurrect Bio 🇬🇧

Series A

AI trait-discovery platform restoring crops' own disease resistance genes without foreign DNA. London/Norwich.

About Resurrect Bio

Resurrect Bio develops genetic resistance traits for crops by utilizing proprietary AI technology and a rapid trait discovery platform, which allows for the identification of resistance genes up to five times faster than traditional methods. Their approach focuses on restoring the crop's own immune system without introducing foreign DNA, ensuring precision targeting against specific pathogens while avoiding chemical inputs and enhancing genetic diversity.

Resurrect Bio is a UK-based company founded in 2021, now around 22 people. FundFinder classes it as AI & ML.

Founder: Tolga Osman Bozkurt (Co-founder/Director).

Its investors also appear on FundFinder's most-active lists for Series A · DeepTech (53 funds), Series A · Climate & Sustainability (53 funds), Series A · Life Sciences (20 funds).

Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.

Want the latest on Resurrect Bio? Our research agent pulls the current description, latest round and full investor base from public sources (about a minute).

Series A · May 2026

InvestorsUIUK Innovation & Science Seed Fund (UKI2S)

UK Innovation & Science Seed Fund (UKI2S) — Evergreen, government-backed pre-seed+ fund managed by Future Planet Capital. · cheques up to £1.5M

Raising your own round? See which European funds fit →